EP 1434
1434. 3 Longevity Drugs I QUIT (And the 4 I Take Instead)
Host Dave Asprey breaks down why three of biohacking’s most trusted longevity drugs don’t hold up under scrutiny, and the science behind the ones that actually might. Metformin, long considered the safe default for anti-aging, blunts the muscle-building signal from resistance training and drains B12 for years after use. Rapamycin has stunning mouse longevity data going back to a 1964 Easter Island soil sample, but the 2025 PEARL trial found no meaningful benefit in healthy adults despite decades of hype. Statins carry a 100-to-1 harm-to-benefit ratio, and Merck holds a patent for pairing them with CoQ10 to offset the muscle pain they cause, a drug they never brought to market. Dave then walks through the yes list: tadalafil, the failed angina drug turned nightly vascular health tool that supports nitric oxide and blood flow to the brain, SGLT2 inhibitors, a diabetes drug class that protects the heart and kidneys while mimicking mild caloric restriction, acarbose, a decades-old gut-focused diabetes drug with some of the strongest lifespan data in mouse studies, and low dose naltrexone, which calms an overactive immune system at a fraction of its addiction-treatment dose. Dave closes with specific dosing for each drug and how to approach a doctor about using them off-label for longevity instead of disease treatment. Essential listening for anyone serious about biohacking, longevity, anti-aging, functional medicine, and separating real pharmaceutical repurposing from pharmaceutical marketing.
Subscribe To The Human Upgrade
In this Episode of The Human Upgrade™...
Back with another solo episode, this one on Big Pharma! Metformin, rapamycin, and statins are three of the most trusted names in longevity, and none of them hold up the way you’ve been told. This episode breaks down the human data behind the drugs everyone assumes are safe, and reveals four lesser-known repurposed pharmaceuticals that might do more for your metabolism, mitochondria, and lifespan.
Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR
Dave walks through why metformin blunts the muscle-building signal your body needs from exercise, why rapamycin’s stunning mouse studies fell apart in the 2025 PEARL trial, and why statins help one person in a hundred while draining the CoQ10 your mitochondria depend on. Then he lays out the yes list: tadalafil for vascular and brain health, SGLT2 inhibitors for metabolic and kidney protection, acarbose for gut and longevity markers, and low dose naltrexone for calming an overactive immune system.
Host Dave Asprey is the father of biohacking, founder of Danger Coffee and Smarter Not Harder, and a New York Times bestselling author who has spent decades studying human performance, functional medicine, and the science of not aging. As co-founder of Unlimited.Life, a concierge longevity practice that runs over $50,000 in lab work per client, he pulls back the curtain on what the data actually shows once you strip away the marketing.
This is essential listening for anyone serious about biohacking, longevity, anti-aging, human performance, brain optimization, and hacking their own biology with real supplements and functional medicine tools instead of guesswork.
You’ll Learn:
- Why metformin can cancel out the muscle gains from resistance training and drain your B12 for years
- What the 2025 PEARL trial actually found when rapamycin was tested in healthy adults
- Why statins carry a 100-to-1 harm-to-benefit ratio and quietly starve your mitochondria of CoQ10
- How tadalafil supports nitric oxide, vascular health, and neuroplasticity at low daily doses
- Why SGLT2 inhibitors trigger ketosis-like metabolic effects and protect kidney function
- How acarbose changes gut bacteria and shows some of the strongest longevity data in mouse studies
- How low dose naltrexone modulates the immune system and reduces neuroinflammation
- How to talk to your doctor about using these drugs off-label for longevity instead of disease treatment
Keywords: Metformin, Rapamycin, Statins, Tadalafil, Cialis, SGLT2 inhibitors, Jardiance, Acarbose, low dose naltrexone, longevity drugs, anti-aging medication, repurposed pharmaceuticals, off-label drugs, mTOR inhibitor, AMPK, autophagy, endothelial dysfunction, CoQ10, insulin resistance, mitochondrial efficiency, senescent cells, nitric oxide, neuroinflammation, vascular health, PEARL trial, Unlimited.Life
Resources:
- Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/
- Dave Asprey’s Latest News | Go to https://daveasprey.com/ to join Inside Track today.
- Danger Coffee: https://dangercoffee.com/discount/dave15?
- My Daily Supplements: SuppGrade Labs (15% Off)
- Favorite Blue Light Blocking Glasses: TrueDark (15% Off)
- Dave Asprey’s BEYOND Conference: https://beyondconference.com
- Dave Asprey’s New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated
- Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/
- Upgrade Labs: https://upgradelabs.com
"It is so much cheaper and easier to just not age than it is to reverse your age."
Dave Asprey
00:00 – Trailer
A quick teaser setting up the episode’s no list and yes list for longevity drugs.
01:01 – Intro
Dave introduces the framework of repurposing pharmaceuticals built for other diseases to target the known causes of aging.
03:48 – Metformin
Why the classic diabetes drug blunts muscle growth from resistance training and causes long-term B12 depletion.
09:18 – Rapamycin
The mTOR inhibitor’s Easter Island origin story, its mixed mouse data, and why the 2025 PEARL trial found no real longevity benefit.
12:55 – Statins
The 100-to-1 harm-to-benefit ratio and why lowering cholesterol may not be doing what you think.
17:28 – Statins & CoQ10
How statins deplete coenzyme Q10 in muscle and mitochondria, and why taking CoQ10 alongside them doesn’t fix the problem.
19:38 – Tadalafil
Why low-dose Cialis supports nitric oxide, vascular health, and blood flow to the brain beyond its original use.
23:43 – SGLT2 Inhibitors
How this diabetes drug class protects the heart and kidneys while mimicking mild caloric restriction and ketosis.
26:12 – Acarbose
The gut-focused diabetes drug with some of the strongest lifespan data in mouse studies.
28:40 – Low-Dose Naltrexone (LDN)
How tiny doses of this addiction drug calm an overactive immune system and lower inflammatory markers.
31:44 – Dosing & Recap
A rundown of specific dosing for each drug on the yes list and how to talk to a doctor about off-label use.
Thank you to our sponsors!
– ALP | Go to alppouch.com, code DAVE for 10% off.
– Timeline | Visit timeline.com/dave and get up to 20% off when you subscribe and save.
– Kinetic | Instead of pushing your system harder, Kenetik feeds your brain the ketones it craves to fuel calm clarity and steady focus. Go to drinkkenetik.com/DAVE and use code DAVE for a discount.
– Visit www.myvitalc.com/davesfav to unlock Dave’s discount
Enjoy the show!
LISTEN:
“Follow” or “subscribe” to The Human Upgrade™ with Dave Asprey on your favorite podcast platform.
REVIEW:
Go to Apple Podcasts at daveasprey.com/apple and leave a (hopefully) 5-star rating and a creative review.
FEEDBACK:
Got a comment, idea or question for the podcast? Submit via this form!
SOCIAL:
Follow @thehumanupgradepodcast on Instagram and Facebook.
JOIN:
Learn directly from Dave Asprey alongside others in a membership group: ourupgradecollective.com.
Subscribe To The Human Upgrade
Similar Episodes
Subscribe To The Human Upgrade
BOOKS
4X NEW YORK TIMES
BEST-SELLING SCIENCE AUTHOR
Smarter
Not Harder
Smarter Not Harder: The Biohacker’s Guide to Getting the Body and Mind You Want is about helping you to become the best version of yourself by embracing laziness while increasing your energy and optimizing your biology.
Also Available
